SOFTOX

INNOVATING RESPIRATORY HEALTH
Targeted anti-infective therapy for
Airway and Lung Infections

SOFTOX
SOLUTIONS

PRESS RELEASE

POSITIVE TOPLINE SAFETY DATA FROM SIS-03

DOSE-ESCALATION PHASE

Dose escalation completed with **no serious adverse events observed**, supporting continued execution of the SIS-03 proof-of-concept / Phase 2a patient phase.

- NO SERIOUS ADVERSE EVENTS OBSERVED
- DOSE ESCALATION COMPLETED
- ADVANCING TO PROOF-OF-CONCEPT PATIENT PHASE
- TARGETING CHRONIC AIRWAY INFECTIONS

PROVEN SAFETY FOUNDATION

Topline safety review of the SIS-03 dose-escalation phase in healthy volunteers showed no serious adverse events and no severe tolerability issues recorded.

NEXT STEP: PROOF-OF-CONCEPT PATIENT PHASE

SIS-03 is now advancing in patients with cystic fibrosis to assess clinical and microbiological signals, including data on bacterial load reduction in patients' airways.

ADDRESSING A LARGE UNMET MEDICAL NEED

Potential relevance across cystic fibrosis and non-CF bronchiectasis with combined market opportunity potential exceeding **USD 5 billion.**

~13,000
patients with cystic fibrosis across the US and EU4+UK

~445,000
patients with non-CF bronchiectasis

>USD 5 billion
total market opportunity

Advancing a novel inhaled anti-infective therapy for patients with chronic airway infections.

Figures, conceptual models and selected visual elements have been developed using AI-assisted visualization tools to support communication of scientific, strategic and operational concepts.

soft-ox.com

SOFTOX

INNOVATING RESPIRATORY HEALTH
Targeted anti-infective therapy
for Airway and Lung Infections



POSITIVE TOPLINE SAFETY DATA FROM SIS-03 DOSE-ESCALATION PHASE

Dose escalation completed with no serious adverse events observed, supporting continued execution of the SIS-03 proof-of-concept/Phase 2a patient phase.

POSITIVE TOPLINE SAFETY REVIEW SUPPORTS CONTINUED SIS-03 EXECUTION

Oslo/Copenhagen – 26 June 2026 – SoftOx Solutions AS ("SoftOx"), a clinical-stage pharmaceutical company developing a novel anti-infective therapy for airway infections, today announces positive topline safety data from the dose-escalation phase of the SIS-03 Phase 2a clinical program.

Reference is made to the stock notice dated 8 June 2026, where the Company announced that the dose-escalation phase of the SIS-03 clinical program had been completed, that the program would advance into the proof-of-concept (PoC") phase, and that the outcome of the safety review would be communicated at a later stage. The safety review has now been completed, and no serious adverse events were observed, nor were any severe tolerability or safety issues recorded during the dose-escalation phase.

SIS-03 is evaluating SoftOx Inhalation Solution ("SIS") as an inhaled anti-infective therapy for chronic airway infections in patients with cystic fibrosis, and the positive outcome of the safety review supports the continued execution of the ongoing PoC/Phase 2a patient phase of SIS-03.

CONTINUED ADVANCEMENT OF THE PROOF-OF-CONCEPT PATIENT PHASE

> *"We are very pleased with the topline safety outcome from the dose-escalation phase of SIS-03. Completing the dose-escalation phase with no serious adverse events observed and no severe tolerability issues recorded is an important step forward for our SIS-03 program. Tolerability is important not only for clinical development, but also for potential future use in real-world treatment settings, where patients need therapies that are both effective and manageable. Concluding this review on a positive note is therefore good news for SoftOx and for the continued development of SIS as a potential treatment option for patients with chronic airway infections."*
>
> Thomas Bjarnsholt, CEO of SoftOx

No additional detailed safety, tolerability, efficacy, or microbiological data are disclosed in this announcement. The Company will provide further updates on the SIS-03 clinical program when relevant milestones are reached.

The SIS-03 clinical trial program is being conducted in collaboration with Rigshospitalet in Copenhagen, Denmark, and the ongoing PoC/Phase 2a patient phase is designed to assess clinical and microbiological signals relevant to establishing proof-of-concept for SIS, including data on bacterial load reduction in patients' airways. This phase of the trial is expected to conclude in H1 2027.

SIS-03 remains separate from the Company's other ongoing SIS-02 clinical program.

POTENTIAL COMMERCIAL RELEVANCE IN CHRONIC AIRWAY INFECTIONS

Total potential market opportunity

- ~13,000 patients with cystic fibrosis across the US and EU4+UK receive chronic inhaled antibiotic therapy
- ~445,000 patients with non-CF bronchiectasis
- >USD 600 million annual market (CF & non-CF bronchiectasis)
- >USD 5 billion total potential market opportunity

SIS-03 CLINICAL PROGRAM STATUS

DOSE ESCALATION COMPLETED	PROOF-OF-CONCEPT PATIENT PHASE	PRIMARY OBJECTIVES	EXPECTED COMPLETION
No serious adverse events observed	Now advancing in cystic fibrosis patients	Assess clinical and microbiological signals, including bacterial load reduction in airways	H1 2027

ABOUT SIS

SoftOx Solutions AS is developing SIS, a novel inhaled anti-infective therapy for respiratory infections in the airways and lungs. SIS targets biofilm-associated infections through a patented, non-antibiotic mechanism designed to reduce the risk of resistance development.

Delivered by nebulizer, SIS is being developed to address bacterial, viral, and fungal pathogens through local delivery directly at the site of infection, without systemic exposure to the remainder of the human body.

Its broad pathogen relevance positions SIS as a distinct therapeutic in respiratory infections.

ABOUT SOFTOX SOLUTIONS AS

SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company developing SIS (SoftOx Inhalation Solution), a novel inhaled anti-infective therapy for the treatment of respiratory infections in the airways and lungs.

The Company is also exploring the potential dual-use relevance of SIS within civilian health security and biological preparedness. SoftOx is listed on Euronext Growth Oslo.

FOR MORE INFORMATION, PLEASE CONTACT

Ulrik Spork
Chairman of the Board
SoftOx Solutions AS
+45 31 38 83 87

Thomas Bjarnsholt
CEO
+45 20 65 98 88

Mail:
ir@soft-ox.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Figures, conceptual models, and selected visual elements have been developed using AI-assisted visualization tools to support communication of scientific, strategic, and operational concepts.

soft-ox.com